AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. In 2024 Stephen Rich and his colleagues ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...
Insulin-producing cells can be genetically modified to hide from the immune system. People with type 1 diabetes must constantly rely on insulin injections or pumps, usually for the rest of their life ...
AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
AUSTIN, Texas, May 7, 2025 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
The study highlights a presymptomatic phase in type 1 diabetes progression, using immune niches to track immune changes ...
This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. In 2024 Stephen Rich and his colleagues ...
Carin Leong: What if people with type 1 diabetes could start making their own insulin? Scientists have just taken a big step in that direction. They treated a patient with 80 million lab-made ...
Richard Oram has received research grants or contracts from Randox and Sanofi. He has also received royalties and license from Randox, consulting fees from Sanofi, Provention Bio, and Janssen and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results